KPRX - Kiora Pharmaceuticals, Inc. Stock Price, Fair Value and News

0.56USD-0.02 (-3.45%)Delayed

Market Summary

USD0.56-0.02

Delayed

-3.45%

KPRX Stock Price

View Fullscreen

KPRX RSI Chart

KPRX Valuation

Market Cap

14.7M

Price/Earnings (Trailing)

5.24

Price/Sales (Trailing)

4.79

EV/EBITDA

1.36

Price/Free Cashflow

2.06

KPRX Price/Sales (Trailing)

KPRX Profitability

EBT Margin

-462.53%

Return on Equity

8.04%

Return on Assets

6.62%

Free Cashflow Yield

48.54%

KPRX Fundamentals

KPRX Revenue

Revenue (TTM)

2.7M

KPRX Earnings

Earnings (TTM)

2.8M

Earnings Growth (Yr)

819.99%

Earnings Growth (Qtr)

693.02%

Breaking Down KPRX Revenue

Last 7 days

14.3%

Last 30 days

9.8%

Last 90 days

-12.5%

Trailing 12 Months

-73.1%

How does KPRX drawdown profile look like?

KPRX Financial Health

Current Ratio

21.02

Debt/Equity

0.01

Debt/Cashflow

25.66

KPRX Investor Care

Shares Dilution (1Y)

1197.07%

Diluted EPS (TTM)

-1.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	3.2M	3.0M	2.7M	2.7M
2018	1.3M	1.4M	1.7M	1.7M
2017	839.9K	753.6K	554.0K	407.5K
2016	0	453.8K	568.5K	683.2K
2015	339.1K	0	0	0
2014	210.4K	215.0K	219.7K	224.4K
2013	0	0	0	205.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kiora Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 29, 2023	tosca melissa	acquired	-	-	30,000	evp finance
Sep 29, 2023	daniels eric joseph	acquired	-	-	62,500	chief development officer
Sep 29, 2023	strem brian m.	acquired	-	-	75,000	president and ceo
Mar 03, 2023	tosca melissa	acquired	-	-	2,400	evp finance
Mar 03, 2023	daniels eric joseph	acquired	-	-	15,600	chief development officer
Mar 03, 2023	strem brian m.	acquired	59,748	3.83	15,600	president and ceo
Oct 21, 2022	strem brian m.	acquired	-	-	12,500	president and ceo
Oct 21, 2022	tosca melissa	acquired	-	-	2,500	evp of finance
Oct 21, 2022	daniels eric joseph	acquired	-	-	10,000	chief development officer
Feb 10, 2022	romano sarah	sold (taxes)	-74.52	0.69	-108	chief financial officer

Which funds bought or sold KPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	2.00	6.00	-%
May 15, 2024	ADAR1 Capital Management, LLC	new	-	776,600	776,600	0.18%
May 15, 2024	Tower Research Capital LLC (TRC)	added	0.34	778	2,956	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	unchanged	-	14,688	56,480	-%
May 15, 2024	Nantahala Capital Management, LLC	new	-	1,341,400	1,341,400	0.08%
May 15, 2024	Alyeska Investment Group, L.P.	new	-	1,553,200	1,553,200	0.01%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	7,308	7,308	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-49,070	-	-%
May 14, 2024	Velan Capital Investment Management LP	new	-	776,600	776,600	0.35%
May 14, 2024	AIGH Capital Management LLC	new	-	1,623,800	1,623,800	0.49%

Are Funds Buying or Selling KPRX?

Are funds buying KPRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KPRX

No. of Funds

Unveiling Kiora Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lincoln park capital fund, llc	9.99%	768,155	SC 13G/A
Feb 13, 2024	lind global fund ii lp	9.9%	845,000	SC 13G/A
Feb 09, 2024	stonepine capital management, llc	9.99%	2,409,058	SC 13G
Feb 07, 2024	hirschman orin	9.9%	2,300,000	SC 13G
Feb 06, 2024	intracoastal capital, llc	1.5%	117,108	SC 13G/A
Jun 13, 2023	lind global fund ii lp	9.9%	345,510	SC 13G
Feb 14, 2023	armistice capital, llc	4.77%	89,997	SC 13G/A
Feb 13, 2023	lind global fund ii lp	7.9%	153,070	SC 13G/A
Feb 13, 2023	lind global macro fund lp	0%	0	SC 13G
Feb 08, 2023	intracoastal capital, llc	9.0%	172,771	SC 13G/A

Recent SEC filings of Kiora Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
May 10, 2024	S-8	Employee Benefits Plan
May 03, 2024	8-K	Current Report
Mar 28, 2024	EFFECT	EFFECT
Mar 28, 2024	424B3	Prospectus Filed
Mar 26, 2024	CORRESP	CORRESP
Mar 25, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Mar 25, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Kiora Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Kiora Pharmaceuticals, Inc. News

Latest updates

Kiora Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-	16,000,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,686,000	-	314,500	242,012
Operating Expenses	31.1%	2,777,906	2,118,649	5,918,568	2,633,012	1,916,667	2,634,998	3,703,035	2,402,048	3,569,442	6,370,993	3,035,089	2,819,504	2,010,182	1,181,637	2,616,607	3,451,274	1,869,800	1,857,360	2,489,456	3,492,378	3,040,330
S&GA Expenses	-100.0%	-	880,550	1,415,844	1,097,294	1,269,458	2,777,957	2,033,367	1,801,878	1,664,791	1,379,025	1,338,616	1,305,865	1,300,143	1,514,514	1,118,752	1,045,145	1,105,904	1,135,883	1,052,202	1,232,677	1,202,531
R&D Expenses	34.4%	1,493,659	1,111,645	1,085,010	1,392,099	438,283	841,617	1,332,153	567,227	707,928	1,001,633	1,628,467	1,439,922	1,280,242	1,011,010	1,497,855	2,406,129	763,896	721,477	1,437,254	2,259,701	1,837,799
EBITDA Margin	1.5%	-4.53	-4.60	-5.03	-5.05	-5.07	-5.08	-5.18	-5.18	-5.18	-5.18	-2.53	-2.53	-2.53	-2.54	-	-	-	-	-	-	-
Interest Expenses	290.1%	223,047	-117,332	49,912	45,087	33,465	-716	7,861	1,237	217	6,301	259	2,033	686	4,186	-	109	108	108	128	304	304
EBT Margin	0%	-4.63	-4.63	-5.10	-5.10	-5.10	-5.10	-5.20	-5.20	-5.20	-5.20	-2.55	-2.55	-2.55	-2.55	-	-	-	-	-	-	-
Net Income	693.0%	13,453,207	-2,268,606	-5,762,941	-2,613,813	-1,868,536	-2,498,446	-5,119,339	-2,400,811	-3,565,014	-6,182,222	-3,034,830	-2,543,015	-2,010,618	-1,185,595	-2,701,846	-3,428,387	-1,837,272	870,809	-2,528,005	-3,123,836	-2,780,255
Net Income Margin	122.4%	1.05	-4.66	-4.74	-4.50	-4.43	-5.06	-6.43	-5.65	-5.71	-5.13	-3.27	-2.88	-2.58	-2.55	-	-	-	-	-	-	-
Free Cashflow	627.8%	13,624,855	-2,581,341	-2,521,097	-1,384,919	-3,069,594	-2,129,000	-2,967,807	-2,498,940	-2,832,386	-2,919,668	-2,270,107	-2,921,310	-2,628,170	-1,709,467	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	209.5%	42,440	13,712	15,896	19,885	16,528	18,678	17,662	15,463	17,636	20,130	25,493	18,100	20,621	15,304	9,245	10,967	12,187	10,113	8,868	10,896	12,439
Current Assets	606.7%	33,482	4,738	6,983	9,023	5,618	7,681	6,624	4,380	6,550	8,991	11,870	4,415	6,991	1,726	3,498	5,197	6,394	4,324	3,113	5,128	6,659
Cash Equivalents	1151.2%	31,280	2,500	5,400	7,952	3,426	5,965	4,851	2,477	5,112	7,900	11,152	3,708	6,655	1,231	2,976	4,734	5,923	3,822	2,500	4,510	5,901
Net PPE	60.2%	13.00	8.00	39.00	45.00	51.00	55.00	59.00	63.00	67.00	74.00	79.00	84.00	84.00	31.00	11.00	14.00	16.00	17.00	24.00	30.00	37.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	3,485	3,485	3,485	3,631	1,526	1,526	1,526	1,526	1,526	1,526	1,526
Liabilities	-0.9%	7,536	7,602	7,792	6,243	6,372	7,271	7,141	6,701	6,378	5,551	8,145	7,646	7,936	5,574	3,284	3,169	2,870	3,490	3,656	2,424	2,400
Current Liabilities	-2.5%	1,593	1,634	2,101	1,883	2,156	3,272	2,994	2,857	2,521	1,610	1,959	1,436	1,426	1,985	930	816	794	1,415	2,176	944	920
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	278	278	278	278	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	278	278	278	278	-	-	-	-	-
Shareholder's Equity	471.3%	34,904	6,110	8,104	13,642	10,156	11,408	10,521	8,762	11,258	14,579	20,507	13,680	15,985	9,730	5,961	7,798	9,318	6,622	5,212	8,472	10,039
Retained Earnings	9.2%	-133,500	-147,000	-144,700	-138,900	-136,300	-134,462	-131,965	-126,845	-124,444	-120,879	-116,355	-113,388	-110,919	-107,108	-105,923	-103,916	-102,199	-100,246	-97,545	-94,116	-92,279
Additional Paid-In Capital	9.9%	168,430	153,192	153,001	152,744	146,683	146,035	142,739	135,701	135,634	135,542	133,638	123,787	123,524	116,784	111,716	111,528	111,331	106,689	102,588	101,996	101,729
Shares Outstanding	240.7%	26,256	7,706	7,689	6,911	1,919	1,796	43,163	13,061	316	317	268	185	184	139	-	-	-	-	-	-	-
Float	-	-	-	-	4,763	-	-	-	6,118	-	-	-	45,594	-	-	-	16,290	-	-	-	7,795	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	627.8%	13,625	-2,581	-2,521	-1,384	-3,069	-2,129	-2,967	-2,498	-2,832	-2,919	-2,270	-2,915	-2,570	-1,709	-1,740	-1,467	-2,400	-2,586	-1,998	-1,422	-2,146
Share Based Compensation	-3.8%	175	182	265	172	136	45.00	130	71.00	216	213	149	263	217	193	188	197	146	203	180	236	233
Cashflow From Investing	-	-	-	-	-	-	-	-	-	6.00	-93.15	-	-5.75	-58.12	-	-	-	-	-	-	-	-
Cashflow From Financing	3234.7%	15,248	-486	-	5,939	513	3,243	5,378	-	-	-212	9,756	-	8,039	218	-	278	4,501	3,908	-15.75	30.00	-1.57

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KPRX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Collaboration Revenue	$ 16,000,000	$ 0
Total Revenue	16,000,000	0
Operating Expenses:
General and Administrative	1,296,441	1,269,458
Research and Development	1,493,659	438,283
Change in Fair Value of Contingent Consideration	(12,194)	208,926
Total Operating Expenses	2,777,906	1,916,667
Operating Income (Loss)	13,222,094	(1,916,667)
Other Income, Net:
Interest Income, Net	223,047	33,465
Other Income, Net	8,066	14,666
Total Other Income, Net	231,113	48,131
Net Income (Loss)	$ 13,453,207	$ (1,868,536)
Net Loss per Common Share - Basic (in usd per share)	$ 0.52	$ (1.00)
Weighted Average Shares Outstanding - Basic (in shares)	25,936,163	1,863,466
Net Loss per Common Share - Diluted (in usd per share)	$ 0.38	$ (1.00)
Weighted Average Shares Outstanding - Diluted (in shares)	35,025,494	1,863,466
Other Comprehensive Income (Loss):
Net Income (Loss)	$ 13,453,207	$ (1,868,536)
Foreign Currency Translation Adjustments	(81,573)	(32,671)
Comprehensive Income (Loss)	$ 13,371,634	$ (1,901,207)

KPRX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and Cash Equivalents	$ 31,276,330	$ 2,454,684
Prepaid Expenses and Other Current Assets	206,671	233,382
Collaboration Receivables	189,905	0
Tax Receivables	1,808,787	2,049,965
Total Current Assets	33,481,693	4,738,031
Non-Current Assets:
Property and Equipment, Net	12,918	8,065
Restricted Cash	4,084	4,267
Intangible Assets and In-Process R&D, Net	8,807,600	8,813,850
Operating Lease Assets with Right-of-Use	94,298	106,890
Other Assets	39,414	40,767
Total Assets	42,440,007	13,711,870
Current Liabilities:
Accounts Payable	323,062	206,260
Accrued Expenses	1,222,078	1,380,666
Operating Lease Liabilities	47,851	47,069
Total Current Liabilities	1,592,991	1,633,995
Non-Current Liabilities:
Contingent Consideration	5,116,765	5,128,959
Deferred Tax Liability	779,440	779,440
Operating Lease Liabilities	46,448	59,822
Total Non-Current Liabilities	5,942,653	5,968,221
Total Liabilities	7,535,644	7,602,216
Commitments and Contingencies (Note 8)
Stockholders’ Equity:
Preferred Stock	4	4
Common Stock, $0.01 Par Value: 50,000,000 shares authorized; 26,256,197 and 7,705,640 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	262,584	77,078
Additional Paid-In Capital	168,429,797	153,192,228
Accumulated Deficit	(133,523,648)	(146,976,855)
Accumulated Other Comprehensive Loss	(264,374)	(182,801)
Total Stockholders’ Equity	34,904,363	6,109,654
Total Liabilities and Stockholders’ Equity	$ 42,440,007	$ 13,711,870

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

CEO	Dr. Brian M. Strem Ph.D.
WEBSITE	kiorapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Kiora Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Kiora Pharmaceuticals, Inc.? What does KPRX stand for in stocks?

KPRX is the stock ticker symbol of Kiora Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kiora Pharmaceuticals, Inc. (KPRX)?

As of Fri May 17 2024, market cap of Kiora Pharmaceuticals, Inc. is 14.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KPRX stock?

You can check KPRX's fair value in chart for subscribers.

What is the fair value of KPRX stock?

You can check KPRX's fair value in chart for subscribers. The fair value of Kiora Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kiora Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kiora Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether KPRX is over valued or under valued. Whether Kiora Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Kiora Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KPRX.

What is Kiora Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, KPRX's PE ratio (Price to Earnings) is 5.24 and Price to Sales (PS) ratio is 4.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPRX PE ratio will change depending on the future growth rate expectations of investors.